natgillin/translations-raw huggingface dataset:
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen. 
IPA iznosila je 32% (24 sata) i 61% (dan 5), što je više nego u slabih metabolizatora koji su primali režim doziranja od 300 mg/75 mg i slično je ostalim skupinama CYP2C19 metabolizatora koje su primale doze od 300 mg/75 mg.
Clopidogrel ratiopharm GmbH is unlikely to affect your ability to drive or to use machines. 
Klopidogrel ratiopharm GmbH ne bi trebao utjecati na Vašu sposobnost upravljanja vozilima ili strojevima.
Musculo-skeletal bleeding (haemarthrosis), arthritis, arthralgia, myalgia 
Mišićnokoštano krvarenje (hemartroza), artritis, artralgija, mijalgija
Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, carbamazepine, and efavirenz. 
Lijekovi su jaki ili umjereni inhibitori CYP2C19 uključuju, primjerice, omeprazol i esomeprazol, fluvoksamin, fluoksetin, moklobemid, vorikonazol, flukonazol, tiklopidin, karbamazepin i efavirenz.
EU/1/09/541/001 - Cartons of 14 film-coated tablets in Alu/Alu blisters EU/1/09/541/002 - Cartons of 28 film-coated tablets in Alu/Alu blisters EU/1/09/541/003 - Cartons of 30 film-coated tablets in Alu/Alu blisters EU/1/09/541/004 - Cartons of 50 film-coated tablets in Alu/Alu blisters EU/1/09/541/005 - Cartons of 84 film-coated tablets in Alu/Alu blisters EU/1/09/541/006 - Cartons of 90 film-coated tablets in Alu/Alu blisters EU/1/09/541/007 - Cartons of 100 film-coated tablets in Alu/Alu blisters EU/1/09/541/008 - Cartons of 7 film-coated tablets in Alu/Alu blisters 
EU/1/09/541/001 - Kutije sa 14 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/002 - Kutije sa 28 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/003 - Kutije sa 30 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/004 - Kutije sa 50 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/005 - Kutije sa 84 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/006 - Kutije sa 90 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/007 - Kutije sa 100 filmom obloženih tableta u Al/Al blisterima EU/1/09/541/008 - Kutije sa 7 filmom obloženih tableta u Al/Al blisterima
Fifteen percent (15.0%) of patients in the clopidogrel group and 21.7% in the placebo group reached the primary endpoint, representing an absolute reduction of 6.7% and a 36% odds reduction in favour of clopidogrel (95% CI: 24, 47%; p< 0.001), mainly related to a reduction in occluded infarct-related arteries. 
Petnaest posto (15,0%) bolesnika u skupini s klopidogrelom i 21,7% u skupini s placebom dostigli su primarni ishod, što predstavlja apsolutno smanjenje od 6,7% i smanjenje izgleda (engl. odds reduction) od 36% u korist klopidogrela (95% CI: 24, 47%; p<0,001), većinom povezano sa smanjenjem okluzije arterija povezanih s infarktom.
Consistent with the above results, in a meta-analysis including 6 studies of 335 clopidogrel-treated subjects at steady state, it was shown that active metabolite exposure was decreased by 28% for intermediate metabolisers, and 72% for poor metabolisers while platelet aggregation inhibition (5 μM ADP) was decreased with differences in IPA of 5.9% and 21.4%, respectively, when compared to extensive metabolisers. 
U skladu s gore navedenim rezultatima, u metaanalizi koja je uključivala 6 studija s 335 osoba liječenih klopidogrelom u stanju dinamičke ravnoteže, pokazano je da je izloženost aktivnom metabolitu smanjena za 28% za umjerene metabolizatore te 72% za slabe metabolizatore, dok je inhibicija agregacije trombocita (5 μM ADP) smanjena s razlikama za vrijednsoti IPA-e od 5,9%, odnosno 21,4%, u usporedbi s brzim metabolizatorima.
swelling in the mouth or skin disorders such as rashes and itching, blisters of the skin. 
- oticanje u ustima ili kožni poremećaji kao što su osip i svrbež te mjehurići na koži.
-Very rare side effects (may affect up to 1 in 10,000 people): 
-Vrlo rijetke nuspojave (mogu se javiti u manje od 1 na 10 000 osoba):
Clopidogrel ratiopharm GmbH contains the active ingredient Clopidogrel which belongs to a group of medicines called antiplatelet medicinal products. 
Klopidogrel ratiopharm GmbH sadrži djelatnu tvar klopidrogel i pripada skupini lijekova koji se nazivaju antitrombocitni lijekovi.
Acute liver failure, hepatitis, abnormal liver function test 
Akutno zatajenje jetre, hepatitis, abnormalni nalazi jetrene funkcije
Contents of the pack and other information What Clopidogrel ratiopharm GmbH contains 
Sadržaj pakiranja i druge informacije Što Klopidogrel ratiopharm GmbH sadrži
Clopidogrel ratiopharm GmbH with food and drink 
Klopidogrel ratiopharm GmbH s hranom i pićem
If a dose is missed: - Within less than 12 hours after regular scheduled time: patients should take the dose immediately and then take the next dose at the regular scheduled time. 
Ako je prošlo manje od 12 sati nakon uobičajenog termina uzimanja lijeka: bolesnik treba odmah uzeti dozu, a sljedeću dozu treba uzeti prema uobičajenom rasporedu.
You have been prescribed Clopidogrel ratiopharm GmbH to help prevent blood clots and reduce the risk of these severe events because: 
Vam je propisan za sprječavanje stvaranja krvnih ugrušaka i smanjivanje opasnosti od ovih ozbiljnih događaja jer:
Clopidogrel ratiopharm GmbH may be taken with or without food. 
Klopidogrel ratiopharm GmbH se može uzimati s obrokom ili bez obroka.
What Clopidogrel ratiopharm GmbH is and what it is used for 
Što je Klopidogrel ratiopharm GmbH i za što se koristi
Serum sickness, anaphylactoid reactions, cross-reactive drug hypersensitivity among thienopyridines (such as ticlopidine, prasugrel) (see section 4.4)*, insulin autoimmune syndrome, which can lead to severe hypoglycemia, particularly in patients with HLA DRA4 subtype (more frequent in the Japanese population)* 
Serumska bolest, anafilaktoidne reakcije, križno reaktivna preosjetljivost na lijekove iz skupine tienopiridina (kao što su tiklopidin, prasugrel) (vidjeti dio 4.4)*, autoimuni inzulinski sindrom koji može dovesti do teške hipoglikemije, osobito u bolesnika s podtipom
Other side effects are: 
Ostale nuspojave uključuju :
Clopidogrel ratiopharm GmbH contains hydrogenated castor oil which may cause stomach upset and diarrhoea. 
Klopidogrel ratiopharm GmbH sadrži hidrogenirano ricinusovo ulje koje može uzrokovati nadražaj želuca i proljev.
They are supplied in cardboard cartons containing 7, 14, 28, 30, 50, 84, 90 and 100 tablets in aluminium blisters. 
Dostupne su u kartonskim kutijama koje sadrže 7, 14, 28, 30, 50, 84, 90
How to store Clopidogrel ratiopharm GmbH Contents of the pack and other information 
Kako čuvati Klopidogrel ratiopharm GmbH Sadržaj pakiranja i druge informacije
-Common side effects (may affect up to 1 in 10 people): Diarrhoea, abdominal pain, indigestion or heartburn. 
-Česte nuspojave (mogu se javiti u manje od 1 na 10 osoba): Proljev, bol u trbuhu, probavne tegobe ili žgaravica.
Reporting of suspected adverse reactions 
Prijava sumnji na nuspojave
After repeated doses of 75 mg clopidogrel per day in subjects with severe renal disease (creatinine clearance from 5 to 15 ml/min), inhibition of ADP-induced platelet aggregation was lower (25%) than that observed in healthy subjects, however, the prolongation of bleeding time was similar to that seen in healthy subjects receiving 75 mg of clopidogrel per day. 
Nakon ponovljenih doza od 75 mg klopidogrela dnevno, inhibicija ADP-om inducirane agregacije trombocita bila je niža (25%) u ispitanika s teško narušenom funkcijom bubrega (klirens kreatinina od 5 do 15 ml/min) u usporedbi sa zdravim ispitanicima, iako je produljenje vremena krvarenja bilo slično onom zabilježenom u zdravih bolesnika koji su primali 75 mg klopidogrela dnevno.
The most common side effect reported with clopidogrel is bleeding. 
Najčešća nuspojava klopidogrela jest krvarenje.
Other concomitant therapy: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. 
Ostala istodobna terapija: s obzirom da se klopidogrel do svog aktivnog metabolita djelomično metabolizira putem CYP2C19, očekuje se da će primjena lijekova koji inhibiraju aktivnost ovog enzima rezultirati smanjenim razinama aktivnog metabolita klopidogrela.
Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). 
embrionalni/fetalni razvoj, porođaj ili postnatalni razvoj (vidjeti dio 5.3).
You have a condition of hardening of arteries (also known as atherosclerosis), and You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease (disturbed blood flow in arms or legs caused by vascular occlusions) or 
- imate otvrdnuće arterija (koje se još zove ateroskleroza) te - ste već imali srčani udar, moždani udar ili imate stanje koje se zove bolest perifernih arterija, ili - ste imali teški oblik boli u prsištu, poznat pod nazivom “nestabilna angina” ili “infarkt miokarda” (srčani udar).
Clopidogrel ratiopharm GmbH contains hydrogenated castor oil 
Klopidogrel ratiopharm GmbH sadrži hidrogenirano ricinusovo ulje
Bullous dermatitis (toxic epidermal necrolysis, Stevens Johnson Syndrome, erythema multiforme, acute generalised exanthematous pustulosis (AGEP)), angioedema, drug-induced hypersensitivity syndrome, drug rash with eosinophilia and systemic symptoms (DRESS), rash erythematous, or exfoliative, urticaria, eczema, lichen planus 
(toksična epidermalna nekroliza, Stevens Johnsonov sindrom, erythema multiforme, akutna generalizirana egzantematozna pustuloza (AGEP)), angioedem, sindrom preosjetljivosti izazvane lijekom, osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (engl.
signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Warnings and precautions'). 
- znakove oštećenja funkcije jetre kao što su žuta boja kože ili očiju (žutica), bez obzira jesu li povezani s krvarenjem koje se pojavljuje kao crvene točkice ispod kože i/ili zbunjenošću
What Clopidogrel ratiopharm GmbH looks like and contents of the pack 
Kako Klopidogrel ratiopharm GmbH izgleda i sadržaj pakiranja
In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery. 
U randomiziranoj, dvostrukoslijepoj studiji s paralelnim skupinama (CLARINET), 906 pedijatrijskih bolesnika (novorođenčad i dojenčad) s cijanotičnom kongenitalnom bolešću srca ublaženom sistemsko-plućnim arterijskim šantom, bilo je randomizirano da primaju klopidogrel u dozi od
The population included 27.8% women, 58.4% patients ≥ 60 years (26% ≥ 70 years) and 
Populacija bolesnika uključivala je 27,8% žena, 58,4%
Thrombotic thrombocytopenic purpura (TTP) (see section 4.4), aplastic anaemia, pancytopenia, agranulocytosis, severe thrombocytopenia, acquired haemophilia A, granulocytopenia, anaemia 
Trombotična trombocitopenična purpura (TTP) (vidjeti dio 4.4), aplastična anemija, pancitopenija, agranulocitoza, teška trombocitopenija,
Thrombocytopenia, leucopenia, eosinophilia 
Trombocitopenija, leukopenija, eozinofilija
If you take more Clopidogrel ratiopharm GmbH than you should 
Ako uzmete više Klopidogrel ratiopharm GmbH nego što ste trebali:
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel ratiopharm GmbH. 
Ako ste trudni ili sumnjate na trudnoću, obavijestite svog liječnika ili ljekarnika prije nego što uzmete
Clopidogrel ratiopharm GmbH 75 mg 
Klopidogrel ratiopharm GmbH 75 mg
-Uncommon side effects (may affect up to 1 in 100 people): 
-Manje česte nuspojave (mogu se javiti u manje od 1 na 100 osoba):
Patients were randomised to clopidogrel (300 mg loading dose followed by 75 mg/day, N = 6,259) or placebo (N = 6,303), both given in combination with ASA (75-325 mg once daily) and other standard therapies. 
Bolesnici su randomizirani u skupine koje su primale klopidogrel (udarna doza od 300 mg, a nakon toga 75 mg/dan, N=6259) ili placebo (N=6303), oboje u kombinaciji s ASK (75 do 325 mg jedanput dnevno) i drugom standardnom terapijom.
The number of patients experiencing the primary endpoint [cardiovascular (CV) death, myocardial infarction (MI), or stroke] was 582 (9.3%) in the clopidogrel-treated group and 719 (11.4%) in the placebo-treated group, a 20% relative risk reduction (95% CI of 10%-28%; p=0.00009) for the clopidogrel-treated group (17% relative risk reduction when patients were treated conservatively, 29% when they underwent percutaneous transluminal coronary angioplasty (PTCA) with or without stent and 10% when they underwent coronary artery bypass graft (CABG). 
Broj bolesnika koji su doživjeli primarni ishod [kardiovaskularna smrt, infarkt miokarda ili moždani udar] bio je 582 (9,3%) u skupini koja je primala klopidogrel i 719 (11,4%) u skupini koja je primala placebo, uz 20%-tno smanjenje relativnog rizika (95% CI od 10% do 28%; p=0,00009) u skupini koja se liječila klopidogrelom (17% smanjenje relativnoga rizika u bolesnika koji su liječeni konzervativno,
Gastrointestinal haemorrhage, diarrhoea, abdominal pain, dyspepsia 
Gastrointestinalno krvarenje, proljev, bol u trbuhu, dispepsija
Package leaflet: Information for the user Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel 
Uputa o lijeku: Informacije za korisnika Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete klopidogrel
Cellulose, microcrystalline (E460) Crospovidone type A Castor oil, hydrogenated 
celuloza, mikrokristalična (E460)
Therefore, concomitant use should be undertaken with caution (see section 4.4). 
Zbog toga je kod istodobne primjene potreban oprez (vidjeti dio 4.4).
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4). 
Stoga je potreban oprez pri istodobnoj primjeni NSAIL, uključujući Cox-2 inhibitore i klopidogrela (vidjeti dio 4.4).
Serious haemorrhage, haemorrhage of operative wound, vasculitis, hypotension 
Ozbiljno krvarenje, krvarenje kirurške rane, vaskulitis, hipotenzija
• Renal impairment Therapeutic experience is limited in patients with renal impairment (see section 4.4). 
Terapijsko iskustvo u bolesnika s narušenom funkcijom bubrega je ograničeno (vidjeti dio 4.4).
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation Esomeprazole is expected to give a similar interaction with clopidogrel. 
Smanjenje je bilo povezano s oslabljenom inhibicijom agregacije trombocita od 39% (udarna doza) i 21% (doza održavanja).
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
PRILOG II A. PROIZVOĐAČI ODGOVORNI ZA PUŠTANJE SERIJE LIJEKA U PROMET
STATEMENT OF ACTIVE SUBSTANCE(S) 
Pomoćna(e) tvar(i)
Haematoma 
Hematomi
While you are taking Clopidogrel ratiopharm GmbH: 
Dok uzimate Klopidogrel ratiopharm GmbH:
Non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction): clopidogrel treatment should be initiated with a single 300 mg loading dose and then continued at 75 mg once a day (with acetylsalicylic acid (ASA) 75 mg-325 mg daily). 
infarkt miokarda): liječenje klopidogrelom treba započeti s jednokratnom udarnom dozom od 300 mg, a zatim nastaviti sa 75 mg jedanput dnevno (uz acetilsalicilatnu kiselinu (ASK) 75 mg do 325 mg dnevno).
Other medicines and Clopidogrel ratiopharm GmbH 
Drugi lijekovi i Klopidogrel ratiopharm GmbH
Clopidogrel ratiopharm GmbH is taken by adults to prevent blood clots (thrombi) forming in hardened blood vessels (arteries), a process known as atherothrombosis, which can lead to atherothrombotic events (such as stroke, heart attack, or death). 
(tromba) u otvrdnutim krvnim žilama (arterijama), a taj poremećaj zove se aterotromboza i može dovesti do aterotrombotičkih događaja (kao što su moždani udar, srčani udar ili smrt).
If you forget to take a dose of Clopidogrel ratiopharm GmbH, but remember within 12 hours of your usual time, take your tablet straight away and then take your next tablet at the usual time. 
Ako zaboravite uzeti jednu dozu Klopidogrel ratiopharm GmbH, ali se toga sjetite u roku od 12 sati,
In particular, in a post-hoc analysis in 2,172 patients (17% of the total CURE population) who underwent stent placement (Stent-CURE), the data showed that clopidogrel compared to placebo, demonstrated a significant RRR of 26.2% favouring clopidogrel for the co-primary endpoint (CV death, MI, stroke) and also a significant RRR of 23.9% for the second co-primary endpoint (CV death, MI, stroke or refractory ischaemia). 
U tzv. post-hoc analizi 2172 bolesnika (17% ukupne CURE populacije) koji su se podvrgli ugradnji stenta (Stent-CURE), podaci su pokazali da je klopidogrel u usporedbi s placebom pokazao značajno smanjenje relativnog rizika od 26,2% za koprimarni ishod
If you experience prolonged bleeding when taking Clopidogrel ratiopharm GmbH. 
Ako pri uzimanju Klopidogrela ratiopharm GmbH imate produljeno krvarenje
Overall, clopidogrel 75 mg/day was comparable to ASA 325 mg/day in CAPRIE regardless of age, gender and race. 
Podaci za klopidogrel u dozi od 75 mg/dan bili su slični podacima za ASK u dozi od 325 mg/dan u CAPRIE
What you need to know before you take Clopidogrel ratiopharm GmbH Do not take Clopidogrel ratiopharm GmbH 
Što morate znati prije nego počnete uzimati Klopidogrel ratiopharm GmbH
Vascular disorders 
Bulozni dermatitis
SSRIs: since SSRIs affect platelet activation and increase the risk of bleeding, the concomitant administration of SSRIs with clopidogrel should be undertaken with caution. 
Selektivni inhibitori ponovne pohrane serotonina (SSRI): budući da lijekovi iz skupine SSRI utječu na aktivaciju trombocita i povećavaju rizik od krvarenja, potreban je oprez prilikom istodobne primjene
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets 
Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete
Glomerulonephritis, blood creatinine increased 
Glomerulonefritis,
Clopidogrel ratiopharm GmbH 75 mg film-coated tablets clopidogrel 
Klopidogrel ratiopharm GmbH 75 mg filmom obložene tablete klopidogrel
You should specifically tell your doctor if you take - medicines that may increase your risk of bleeding such as: o oral anticoagulants, medicines used to reduce blood clotting, o a non-steroidal anti-inflammatory medicine, usually used to treat painful and/or inflammatory conditions of muscle or joints o heparin or any other injectable medicine used to reduce blood clotting o ticlopidine, other antiplatelet agent, o a selective serotonin reuptake inhibitor (including but not restricted to fluoxetine or fluvoxamine), medicines usually used to treat depression, - omeprazole or esomeprazole, medicines to treat upset stomach - fluconazole or voriconazole medicines to treat fungal infections 
o selektivne inhibitore ponovne pohrane serotonina (uključujući, ali ne ograničeno na fluoksetin i fluvoksamin), lijekove koji se obično koriste za liječenje depresije, - omeprazol ili esomeprazol, lijekove za smanjenje želučanih tegoba, - flukonazol ili vorikonazol, lijekove koji se primjenjuju za liječenje gljivičnih infekcija, - efavirenz, lijek koji se primjenjuje za liječenje HIV (virus humane imunodeficijencije) infekcija, - antiretrovirusne lijekove (lijekovi za liječenje infekcije HIV-om), - karbamazepin, lijek koji se primjenjuje za liječenje nekih oblika epilepsije, - moklobemid, lijek za liječenje depresije, - repaglinid, lijek za liječenje dijabetesa,
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel ratiopharm GmbH. 
Ako se bilo što od navedenog odnosi na Vas, ili niste sigurni, obratite se svom liječniku prije uzimanja
(alone or in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician. 
Bolesnicima koji uzimaju klopidogrel (kao monoterapiju ili u kombinaciji s ASK) potrebno je objasniti da će krvarenje možda trajati dulje nego obično i da moraju obavijestiti liječnika o bilo kakvom neočekivanom krvarenju (s obzirom na mjesto i trajanje krvarenja).
Patients received clopidogrel (300 mg loading dose, followed by 75 mg/day, n=1752) or placebo (n=1,739), both in combination with ASA (150 to 325 mg as a loading dose, followed by 75 to 162 mg/day), a fibrinolytic agent and, when appropriate, heparin. 
(najprije udarnu dozu od 300 mg, a nakon toga dozu od 75 mg na dan, n=1752) ili placebo (n=1739), oboje u kombinaciji s ASK (150 do 325 mg kao udarna doza nakon čega je slijedila doza od 75 do
If you forget to take Clopidogrel ratiopharm GmbH 
Ako ste zaboravili uzeti Klopidogrel ratiopharm GmbH:
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel ratiopharm GmbH in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever. 
Klopidogrel ratiopharm GmbH u kombinaciji s acetilsalicilatnom kiselinom, tvari prisutnom u mnogim lijekovima za ublažavanje boli i snižavanje temperature.
Haematuria 
Vrtoglavica
The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY and COMMIT studies are discussed below. 
Klinički značajne nuspojave opažene u studijama CAPRIE,
How to take Clopidogrel ratiopharm GmbH 
Kako uzimati Klopidogrel ratiopharm GmbH
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel. 
Ako je potrebno hitno korigirati produljeno vrijeme krvarenja,
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state). 
umjereni i slabi), procijenjen je farmakokinetički i antitrombocitni odgovor primjenom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana (stanje dinamičke ravnoteže).
Musculoskeletal , connective tissue and bone disorders 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva
Tablet core: 
Propuštena doza:
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p=0.045), which corresponds, for every 1,000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event. 
[95% CI: 0,2 do 16,4]; p=0,045) što odgovara broju od dodatnih 10 bolesnika kojima je spriječen novi ishemijski događaj na svakih 1000 bolesnika liječenih 2 godine [CI: 0 do 20]. Analiza ukupne smrtnosti sekundarnog ishoda studije nije pokazala značajnu razliku između klopidogrela (5,8%) i
If you become pregnant while taking Clopidogrel ratiopharm GmbH, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant. 
odmah se posavjetujte s liječnikom, jer nije preporučeno uzimati klopidogrel za vrijeme trudnoće.
Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known” 
Produljeno vrijeme krvarenja, smanjeni broj neutrofila, smanjeni broj trombocita
Gastric ulcer and duodenal ulcer, gastritis, vomiting, nausea, constipation, flatulence 
Ulkus želuca i dvanaesnika, gastritis,
How to store Clopidogrel ratiopharm GmbH 
Kako čuvati Klopidogrel ratiopharm GmbH